Kerendia Reduces Cardiovascular Deaths in Patients with Cardio-Kidney-Metabolic Conditions

Results from the FINE-HEART pooled analysis of three Phase III clinical trials highlighted the potential of finerenone in treating high-risk cardiovascular patients.